Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16
Benzinga Newsdesk 4 months ago
NewsInitiationAnalyst RatingsPrice Target
Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $16.
Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $16.